RNS Number : 4527O

Deltex Medical Group PLC

09 February 2021

                                           9 February 2021 
                                       Deltex Medical Group plc 
                                  ("Deltex Medical" or the "Company") 
                                           Director Dealing 
       Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring 
       ("ODM"), announces that Andrew Mears, Chief Executive Officer of the Company, advised the 
       Company today that he has transferred 3,076,923 Ordinary Shares of 1p each in the Company 
 ("Ordinary Shares") which he purchased in the subscription on 21 December 2020 into his Self-Invested 
            Personal Pension. His beneficial holding remains unchanged by this transaction. 
                               For further information, please contact:- 
                       Deltex Medical Group plc                   01243 774 837 
               Andy Mears, CEO                            investorinfo@deltexmedical.com 
                                David Moorhouse, Group Finance Director 
                                       Nominated Adviser & Broker 
                       Arden Partners plc                         020 7614 5900 
                                            Benjamin Cryer 
                                            Dan Gee-Summons 
                                             Joint Broker 
                       Turner Pope Investments (TPI) Ltd          0203 657 0050 
                    Andy Thacker                               info@turnerpope.com 
                                             Zoe Alexander 
                                           Notes for Editors 
   Deltex Medical manufactures and markets haemodynamic monitoring technologies which are primarily 
    used in critical care and general surgical procedures. Deltex Medical's proprietary oesophageal 
 Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity in the central circulation 
     in real time. Minimally invasive, easy to set-up and quick to focus, the technology generates 
   a low-frequency ultrasound signal which is highly sensitive to changes in blood flow and measures 
     such changes in 'real time'. Deltex Medical is the only company in the enhanced haemodynamic 
      space to have built a robust and credible evidence base demonstrating both the clinical and 
      economic benefits of its core technology: TrueVue Doppler. This technology has been proven 
     in a wide range of clinical trials to reduce complications suffered by patients after surgery 
                              and consequently can save hospitals money. 
     Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor platform now provides clinicians 
   with two further advanced haemodynamic monitoring technologies. TrueVue Impedance is an entirely 
      non-invasive monitoring technology which transmits low magnitude, high frequency electrical 
    signals through the thorax and measures the changes to this signal when the heart pumps blood. 
  TrueVue PressureWave uses the peripheral blood pressure signal analysis to give doctors information 
 on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically 
                                           stable patients. 
                                              Group goal 
      Haemodynamic management is now becoming widely accepted as a vital part of the anaesthesia 
  protocols for surgical patients, as well as treating ventilated intensive care patients, including 
       ventilated COVID-19 patients. Consequently, the Group's focus is on maximising value from 
   the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical 
      practice around the world. The Group aims to provide clinicians with a single platform - a 
  'haemodynamic workstation' - which offers them a range of technologies from simple to sophisticated 
    to be deployed according to the patient's clinical condition as well as the skill and expertise 
     of the user. Doing this will enable the Group to partner with healthcare providers to support 
                       modern haemodynamic management across the whole hospital. 
 The Group is currently in the implementation phase of achieving this goal in a number of territories 
      worldwide, operating directly in the UK and the USA, and via agreements with approximately 
                                       40 distributors overseas. 

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                              Andrew Mears 
     --------------------------------  ----------------------------------------- 
 2.   Reason for the Notification 
 a)   Position/status                   CEO 
     --------------------------------  ----------------------------------------- 
 b)   Initial notification/amendment    Initial notification 
     --------------------------------  ----------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                              Deltex Medical Group plc 
     --------------------------------  ----------------------------------------- 
 b)   LEI                               213800XN34P6LI8J6M39 
     --------------------------------  ----------------------------------------- 
 4.   Details of the transaction(s):section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv)each place where transactions have been 
 a)   Description of the Financial      Ordinary Shares of 1 p each 
       instrument, type of instrument 
     --------------------------------  ----------------------------------------- 
      Identification code               GB0059337583 
     --------------------------------  ----------------------------------------- 
 b)   Nature of the Transaction         Transfer into SIPP 
     --------------------------------  ----------------------------------------- 
 c)   Price(s) and volume(s)            3,076,923 Ordinary shares 
     --------------------------------  ----------------------------------------- 
 d)        Aggregated information 
             *    Aggregated volume      3,076,923 
                                          1.3 pence 
             *    Price 
     --------------------------------  ----------------------------------------- 
 e)   Date of the transaction           8 February 2021 
     --------------------------------  ----------------------------------------- 
 f)   Place of the transaction          London Stock Exchange, AIM Market (XLON) 
     --------------------------------  ----------------------------------------- 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

February 09, 2021 05:31 ET (10:31 GMT)